To examine the safety and effectiveness of extended-release carbamazepine in the treatment of children and adolescents aged 10-17 years with acute manic or mixed bipolar I disorder.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
161
Safety and tolerability as assessed by the occurrence of treatment emergent adverse events and evaluations of clinical laboratory values, physical examinations, vital signs and ECG data after 6 months of treatment.
Time frame: 6 months
Reduction of bipolar symptoms as assessed by the Young Mania Rating Scale (YMRS), Clinical Global Impressions Scale (CGI) and Children's Depression Rating Scale (CDRS-S) after 6 months of treatment.
Time frame: 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
11 Shire Clinical Research Site
Altamonte Springs, Florida, United States
17 Segal Institute for Clinical Research
Fort Lauderdale, Florida, United States
19 Sarkis Clinical Trials
Gainesville, Florida, United States
23 Shire Clinical Research Site
Jacksonville, Florida, United States
21 Scientific Clinical Research
North Miami, Florida, United States
14 Northlake Medical Research
Decatur, Georgia, United States
04 Mountain West Clinical Trials
Eagle, Idaho, United States
25 Capstone Clinical Research
Libertyville, Illinois, United States
15 Psychiatric Associates
Overland Park, Kansas, United States
27 Owensboro Behavioral Care
Owensboro, Kentucky, United States
...and 16 more locations